论文部分内容阅读
目的 :探讨对耐多药肺结核患者运用自体骨髓干细胞输注治疗的临床疗效以及安全性。方法 :选取2011年1月~2012年12月治疗的耐多药肺结核病患者80例,其中40例患者接受自体骨髓干细胞输注和常规规范抗结核治疗(观察组),40例患者接受常规规范抗结核治疗(对照组),观察两组治疗疗效、痰菌阴转以及不良反应情况。结果 :随访两组患者治疗后24个月,观察组治疗有效率为50.00%,对照组有效率15.00%,两组治疗疗效通过Mann-Whitney U检验分析,差异有统计学意义;观察组治疗6个月和24个月痰菌阴转率高于对照组;观察组治疗12个月痰菌阴转率为40.00%,高于对照组的5.00%,差异有统计学意义;观察组不良反应率为30.00%,对照组不良反应发生率为40.00%,差异无统计学意义。结论 :自体骨髓干细胞输注治疗耐多药肺结核具有可靠的临床疗效,且安全性和耐受性较好。
Objective: To investigate the clinical efficacy and safety of infusion of autologous bone marrow stem cells in patients with multidrug-resistant pulmonary tuberculosis. Methods: Totally 80 MDR-TB patients treated from January 2011 to December 2012 were selected. Forty patients received infusion of autologous bone marrow stem cells and conventional nontuberculous therapy (observation group), 40 patients underwent routine norm Anti-TB treatment (control group), observe the curative effect of the two groups, sputum negative conversion and adverse reactions. Results: Follow-up 24 months after treatment, the effective rate of the observation group was 50.00% and that of the control group was 15.00%. The therapeutic effect of the two groups was analyzed by Mann-Whitney U test, the difference was statistically significant. The observation group treated 6 Months and 24 months sputum negative conversion rate was higher than the control group; observation group 12 months sputum negative conversion rate was 40.00%, higher than the control group 5.00%, the difference was statistically significant; the adverse reaction rate 30.00%, the incidence of adverse reactions in the control group was 40.00%, the difference was not statistically significant. CONCLUSION: Autologous transplantation of bone marrow stem cells for the treatment of multidrug-resistant pulmonary tuberculosis has reliable clinical efficacy and is safe and well tolerated.